T-ICAHT: A New Grading System for Thrombocytopenia After CAR T-cell Therapy with Prognostic Significance

Highlight

• T-ICAHT is a newly developed grading system assessing thrombocytopenia after CD19 CAR T-cell therapy, based on depth, duration, and timing.
• Early (days 0-30) and late (days 31-100) thrombocytopenia are frequent, with severe cases occurring in approximately one-fifth to one-eighth of patients.
• Higher T-ICAHT grades correlate with increased transfusion requirements, more bleeding events, and independently predict worse overall survival.
• The grading system’s prognostic validity is confirmed across multiple hematologic malignancies, supporting its integration into the ICAHT framework.

Study Background and Disease Burden